Humacyte (HUMA) Projected to Post Earnings on Friday

Humacyte (NASDAQ:HUMA) is projected to announce its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $1.3490 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:00 AM ET.

Humacyte Trading Down 6.6%

Shares of HUMA opened at $0.79 on Wednesday. Humacyte has a 12-month low of $0.70 and a 12-month high of $3.10. The firm has a market capitalization of $148.77 million, a P/E ratio of -3.45 and a beta of 1.89. The firm has a 50-day moving average price of $1.06 and a 200 day moving average price of $1.29. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HUMA. Virtu Financial LLC acquired a new stake in Humacyte during the 4th quarter worth $252,000. XTX Topco Ltd boosted its position in shares of Humacyte by 236.1% in the 4th quarter. XTX Topco Ltd now owns 650,858 shares of the company’s stock worth $625,000 after buying an additional 457,236 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in Humacyte during the 4th quarter valued at $201,000. Millennium Management LLC lifted its stake in shares of Humacyte by 129.5% during the 4th quarter. Millennium Management LLC now owns 2,631,990 shares of the company’s stock worth $2,528,000 after purchasing an additional 1,485,152 shares during the period. Finally, Engineers Gate Manager LP acquired a new position in Humacyte during the fourth quarter worth approximately $82,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on HUMA shares. Benchmark decreased their target price on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. UBS Group reiterated a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Tuesday, March 17th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Humacyte presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.14.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.